As previously described in this review, IGF-1 and IGF-2 interactions with their receptors are modulated by IGFBPs.85 Although the major signaling pathways activated by the IGF-1R have been identified, no drugs have yet been successful in clinical trials to target IGF-1R network in breast cancer therapeutically. This evidence concerns the gene IGF2 and breast carcinoma.